Related Experiment Video

Updated: Aug 19, 2026

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells
09:03

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

Antiangiogenic therapy: creating a unique "window" of opportunity

Michelle I Lin1, William C Sessa

  • 1Yale University School of Medicine, Vascular Cell Signaling and Therapeutics Program, Boyer Center for Molecular Medicine, 295 Congress Avenue, New Haven, CT 06536, USA.

Cancer Cell
|December 21, 2004
PubMed

Insights

Antiangiogenic therapy for solid tumors normalizes tumor vasculature, improving oxygen delivery. This creates a therapeutic window for enhanced radiation and chemotherapy effectiveness.

Area of Science:

  • Oncology
  • Vascular Biology
  • Cancer Therapeutics

Background:

  • Antiangiogenic therapy targets tumor vasculature, reducing tumor growth.
  • VEGF signaling neutralization unexpectedly normalizes tumor blood vessels.

Discussion:

  • Vessel normalization involves pericyte recruitment, stabilizing vasculature.
  • This process improves oxygen delivery to hypoxic tumor regions.
  • Angiopoietin-1 and matrix metalloproteinases mediate normalization.

Key Insights:

  • A 'normalization window' enhances tumor sensitivity to treatments.
  • Improved vascular function facilitates chemotherapy drug delivery.
  • Transient vessel stabilization offers a therapeutic opportunity.

Outlook:

  • Leveraging the normalization window can optimize antiangiogenic strategies.
  • Combination therapies may improve solid tumor treatment outcomes.
  • Further research into vascular normalization mechanisms is warranted.

More Related Videos

Assessing Therapeutic Angiogenesis in a Murine Model of Hindlimb Ischemia07:48

Assessing Therapeutic Angiogenesis in a Murine Model of Hindlimb Ischemia

Published on: June 8, 2019

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis09:33

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis

Published on: March 20, 2026

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...